Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC15A1 | P46059 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.52 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | LAP3 | P28838 | 1/20 | 0.49 |
| ▸ | ALPI | P09923 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | XIAP | P98170 | 1/20 | 0.49 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.47 |
| ▸ | CDC25B | P30305 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28704585 | 1.00 | SLC15A1 (0.63) | SLC15A1ALDH1A1MAPK1L3MBTL1EPHX1 | |
| Hydrochloric Acid SCHEMBL14119062 | 0.98 | SLC15A1 (0.62) | SLC15A1ALDH1A1MAPK1L3MBTL1EPHX1 | |
| Hydrochloric Acid SCHEMBL15928827 | 0.98 | SLC15A1 (0.62) | SLC15A1ALDH1A1MAPK1L3MBTL1EPHX1 | |
| Hydrochloric Acid SCHEMBL19511476 | 0.90 | ALDH1A1 (0.59) | SLC15A1ALDH1A1MAPK1L3MBTL1LTA4H | |
| SCHEMBL20364073 | 0.87 | ALDH1A1 (0.56) | SLC15A1ALDH1A1MAPK1L3MBTL1LTA4H | |
| SCHEMBL28116748 | 0.87 | ALDH1A1 (0.56) | SLC15A1ALDH1A1MAPK1L3MBTL1LTA4H | |
| SCHEMBL6822911 | 0.87 | ALDH1A1 (0.56) | SLC15A1ALDH1A1MAPK1L3MBTL1LTA4H | |
| SCHEMBL4624347 | 0.87 | ALDH1A1 (0.56) | SLC15A1ALDH1A1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL6822910 | 0.87 | ALDH1A1 (0.56) | SLC15A1ALDH1A1MAPK1L3MBTL1LTA4H | |
| SCHEMBL1646942 | 0.85 | EPHX1 (0.50) | SLC15A1ALDH1A1EPHX1ALPIPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3994122-A1 | N-FORMYLHYDROXYLAMINES AS NEPRILYSIN (NEP) INHIBITORS, IN PARTICULAR AS MIXED INHIBITORS OF AMINOPEPTIDASE N (APN) AND NEPRILYSIN (NEP) | Pharmaleads (FR) | 2022-05-11 | — | — | EP | disclosed |
| CN-114341109-A | N-formyl hydroxylamines as inhibitors of enkephalinase (NEP), in particular as mixed inhibitors of aminopeptidase N (APN) and enkephalinase (NEP) | 领先药物公司 | 2022-04-12 | — | — | CN | disclosed |
| US-8802818-B2 | Prostaglandin-F2 alpha receptor modulators and uses thereof | LUBELL WILLIAM D (CA) | 2014-08-12 | — | — | US | disclosed |
| US-8802818-B2 | Prostaglandin-F2 alpha receptor modulators and uses thereof | LUBELL WILLIAM D (CA) | 2014-08-12 | — | — | US | disclosed |
| US-20120309690-A1 | PROSTAGLANDIN-F2 ALPHA RECEPTOR MODULATORS AND USES THEREOF | LUBELL WILLIAM D (CA) | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309690-A1 | PROSTAGLANDIN-F2 ALPHA RECEPTOR MODULATORS AND USES THEREOF | PTGFR, PTGER1, PTGER2 | SLC15A1 2122/4885ALDH1A1 1535/4885MAPK1 2745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.